Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

AstraZeneca